Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
NCT07342179

CAR-T Immunomonitoring in Multiple Myeloma (CART I5M)

Led by Poitiers University Hospital · Updated on 2026-02-18

60

Participants Needed

1

Research Sites

346 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Multiple myeloma patients can be treated with cell therapy, which uses some of their own modified white blood cells (T lymphocytes) to target a protein (BCMA, or B-cell maturation antigen) found on the surface of the myeloma plasma cells. These modified T lymphocytes are called CAR T cells (chimeric antigen receptor T cells). The long-term persistence of these modified lymphocytes, or CAR-BCMA, is a recognized indicator of a good response to treatment. This research aims to study certain markers related to CAR-BCMA cell persistence. This research will be carried out in collaboration with the Laboratory of Ischemia Reperfusion, Metabolism and Sterile Inflammation in Transplantation (IRMETIST) INSERM unit U1313, located at the University of Poitiers. The proposed project will contribute to better patient care in the field of oncology, by identifying immunological cellular markers predictive of an effective response to anti-cancer treatments and/or immunotherapeutic targeting.

CONDITIONS

Official Title

CAR-T Immunomonitoring in Multiple Myeloma (CART I5M)

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patient aged 18 and over
  • Patient with Multiple Myeloma according to international recommendations
  • Patient about to receive CAR-T cell therapy in accordance with the rules and authorizations in France
Not Eligible

You will not qualify if you...

  • Severely impaired physical and/or psychological health that may affect compliance with the study
  • Simultaneous participation in another study with an ongoing exclusion period
  • Individuals receiving enhanced protection such as minors, pregnant or breastfeeding women, individuals deprived of liberty, residents in healthcare or social care facilities, adults under legal guardianship, and patients in emergency situations

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Chu de Poitiers

Poitiers, France, 86000

Actively Recruiting

Loading map...

Research Team

A

ARTHUR BOBIN

CONTACT

S

STEPHANIE NOEL

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

HEALTH_SERVICES_RESEARCH

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

CAR-T Immunomonitoring in Multiple Myeloma (CART I5M) | DecenTrialz